ecancermedicalscience

Special Issue

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?

3 Dec 2020
Elham Sajjadi, Konstantinos Venetis, Cristian Scatena, Nicola Fusco

Precision immunotherapy is a crucial approach to improve the efficacy of anti-cancer treatments, particularly in the metastatic setting. In this respect, accurate patient selection takes advantage of the multidimensional integration of patients’ clinical information and tumour-specific biomarkers status. Among these biomarkers, programmed death-ligand 1, tumour-infiltrating lymphocytes, microsatellite instability, mismatch repair and tumour mutational burden have been widely investigated. However, novel tumour-specific biomarkers and testing methods will further improve patients’ outcomes. Here, we discuss the currently available strategies for the implementation of a precision immunotherapy approach in the clinical management of metastatic solid tumours and highlight future perspectives.

Related Articles

Tooba Ali, Nasir Ali, Syed Aun Hasan, Nawazish Zehra, Laraib Khan, Maham Khan, Mariam Hina, Bilal Ahmed, Fabiha Shakeel, Ahmed Nadeem Abbasi, Bilal Mazhar Qureshi, Asim Hafiz, Maria Tariq, Sehrish Abrar
Manuel Bazan, Claudia Gutiérrez-Villamil, Amalia Peix, Saurabh Malhotra, Fernando Dettori, Roberto N Agüero, Belén Flores, Claudio Tinoco Mesquita, Enrique Hiplan, Teresa Massardo, Isabel Berrocal, José A Coss, Verónica Gómez, María C Fonseca, Karla Abadí, Adriana Puente, Víctor Rosales, Luis F Chen, Yariela Herrera, Marina Arnal, Aurelio Mendoza, Omar Alonso, Jorge E Aguiar, Carla Cueva, Enrique Estrada, Diana Páez
Sudarshan Govender, Tamsin K Phillips, Fiona M Walter, Sarah Day, Bothwell Guzha, Suzanne E Scott, Zvavahera M Chirenje, John E Ataguba, Nomonde Mbatani, Nazia Fakie, Jennifer Moodley
Abbas A Abdus-salam, Chiamaka G Ehiedu, Olabisi T Ojo, Atara I Ntekim, Mutiu A Jimoh, Mariam A Bashir, Daluchukwu J Obi, Abel S Anegbe